<DOC>
	<DOCNO>NCT00165828</DOCNO>
	<brief_summary>Patients focal epileptic seizure without generalization present treat one two antiepileptic drug eligible study , provide fulfill inclusion criterion none exclusion criterion . Following baseline phase 8 week duration , patient randomise receive initial daily dose 50 mg zonisamide first week . The daily dose increase 200 mg zonisamide group A 400 mg zonisamide group B , respectively . After eight week treatment , daily dose group A increase 300 mg case insufficient efficacy . Control assessments perform begin study end prospective baseline phase , applicable 4 , 8 , 12 , 16 week . At end first , second , third treatment week , end week six , patient additionally contact telephone . Efficacy safety parameter assess baseline , control visit , end study .</brief_summary>
	<brief_title>Efficacy Safety add-on Treatment With Zonisamide Adults With Focal Epileptic Seizures With Without Secondary Generalization</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<criteria>Inclusion criterion screen : Adult age 18 year 74 year Focal epileptic seizure without secondary generalization Present treatment one two antiepileptic drug ( constant dosage 8 week baseline phase prior initiation treatment zonisamide ) . Stimulation vagus nerve permit count antiepileptic drug . For woman childbearing potential ( postmenopausal 1 year ) : possible pregnancy study exclude ( hysterectomy , sterilization simultaneous application two recognize method contraception ( oral contraceptive ) For male patient partner childbearing potential : safe method contraception practice study participation Written consent participate study Inclusion criterion randomisation : At least 6 focal clonicotonic seizure document completely seizure diary patient chart 8 prospective retrospective week baseline phase . Exclusion criterion screen : Epileptic state past year Nonepileptic fit Generalized epilepsy More 4 week seizure freedom baseline phase Concomitant progressive CNS disease include progressive myoclonus epilepsy Concomitant treatment vigabatrine / topiramate Hepatic and/or renal insufficiency ( creatine &gt; 2mg % GPT &gt; 2 time ULN ) Body weight â‰¤ 40 kg ( History ) kidney stone ; erythrocyturia , family history ( parent , child , brother sister grandparent ) kidney stone ( History ) drug and/or alcohol dependence Active psychosis Suicide attempt past 3 year Pretreatment zonisamide Known hypersensitivity sulfonamide concomitant treatment neuroleptic drug pregnant breast feed woman participation another therapy study within 3 month prior study blood donation plan within 4 week participation study elective surgery plan participation study patient willing capable meet study demand patient agree forward his/her pseudonymous data patient without legal competence Exclusion criterion randomisation : More 4 consecutive week freedom seizure baseline phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Epilepsy</keyword>
</DOC>